Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
171,717,172
-
Number of holders
-
163
-
Total 13F shares, excl. options
-
128,192,171
-
Shares change
-
+4,730,717
-
Total reported value, excl. options
-
$1,915,159,649
-
Value change
-
+$58,936,160
-
Put/Call ratio
-
0.2%
-
Number of buys
-
102
-
Number of sells
-
-55
-
Price
-
$14.94
Significant Holders of Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RLAY) as of Q4 2022
190 filings reported holding RLAY - Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2022.
Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RLAY) has 163 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 128,192,171 shares
of 171,717,172 outstanding shares and own 75% of the company stock.
Largest 10 shareholders include SB INVESTMENT ADVISERS (UK) LTD (27,904,963 shares), VANGUARD GROUP INC (10,384,218 shares), FMR LLC (9,733,848 shares), BlackRock Inc. (7,997,985 shares), STATE STREET CORP (6,264,497 shares), PRICE T ROWE ASSOCIATES INC /MD/ (4,493,004 shares), JPMORGAN CHASE & CO (4,469,898 shares), Bellevue Group AG (4,204,820 shares), EcoR1 Capital, LLC (4,163,824 shares), and BVF INC/IL (3,876,021 shares).
This table shows the top 163 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.